Phase I Clinical Trial of a Recombinant Blood Stage Vaccine Candidate for Plasmodium falciparum Malaria Based on MSP1 and EBA175

Article English OPEN
Chitnis, Chetan E. ; Mukherjee, Paushali ; Mehta, Shantanu ; Yazdani, Syed Shams ; Dhawan, Shikha ; Shakri, Ahmad Rushdi ; Bharadwaj, Rukmini ; Gupta, Puneet Kumar ; Hans, Dhiraj ; Mazumdar, Suman ; Singh, Bijender ; Kumar, Sanjeev ; Pandey, Gaurav ; Parulekar, Varsha ; Imbault, Nathalie ; Shivyogi, Preethi ; Godbole, Girish ; Mohan, Krishna ; Leroy, Odile ; Singh, Kavita ; Chauhan, Virander S. (2015)
  • Publisher: Public Library of Science
  • Journal: PLoS ONE, volume 10, issue 4 (issn: 1932-6203, eissn: 1932-6203)
  • Related identifiers: doi: 10.1371/journal.pone.0117820, pmc: PMC4415778
  • Subject: Q | R | Research Article | Science | Medicine
    mesheuropmc: parasitic diseases

Background A phase I randomised, controlled, single blind, dose escalation trial was conducted to evaluate safety and immunogenicity of JAIVAC-1, a recombinant blood stage vaccine candidate against Plasmodium falciparum malaria, composed of a physical mixture of two recombinant proteins, PfMSP-119, the 19 kD conserved, C-terminal region of PfMSP-1 and PfF2 the receptor-binding F2 domain of EBA175. Method Healthy malaria naïve Indian male subjects aged 18–45 years were recruited from the volunteer database of study site. Fifteen subjects in each cohort, randomised in a ratio of 2:1 and meeting the protocol specific eligibility criteria, were vaccinated either with three doses (10μg, 25μg and 50μg of each antigen) of JAIVAC-1 formulated with adjuvant Montanide ISA 720 or with standard dosage of Hepatitis B vaccine. Each subject received the assigned vaccine in the deltoid muscle of the upper arms on Day 0, Day 28 and Day 180. Results JAIVAC-1 was well tolerated and no serious adverse event was observed. All JAIVAC-1 subjects sero-converted for PfF2 but elicited poor immune response to PfMSP-119. Dose-response relationship was observed between vaccine dose of PfF2 and antibody response. The antibodies against PfF2 were predominantly of IgG1 and IgG3 isotype. Sera from JAIVAC-1 subjects reacted with late schizonts in a punctate pattern in immunofluorescence assays. Purified IgG from JAIVAC-1 sera displayed significant growth inhibitory activity against Plasmodium falciparum CAMP strain. Conclusion Antigen PfF2 should be retained as a component of a recombinant malaria vaccine but PfMSP-119 construct needs to be optimised to improve its immunogenicity. Trial Registration Clinical Trial Registry, India CTRI/2010/091/000301
Share - Bookmark